To credit, they completed its phase 1 trial, demonstrated safety...

To credit, they completed its phase 1 trial, demonstrated safety and bio kinetics as expected. And shown superior contrast with MRI.

Where it failed, was in the Bob boy scout ethics on not incentivising recruitment of patients, which then took glacial period to complete. I hope Bob can think for a moment about two different universes.

One where incentive payments accelerated the phase 1, to within the scope of a year. And the sp momentum was maintained. Thereby raising money at a premium to accelerate further trials.
The other, well thats where we are right now.

Where it goes from here, is to phase 2 trials, and needs to recapture the markets attention of the prize it is seeking, the holy grail of early definitive detection with a non radioactive injectable, without biopsy, over multiple cancer types. The ability to locate with MRX radar map in an area of interest, tiny sizes, where there might be a blood test or other indicator to do so, but catching the cancer before it grows. Then over to MRI, get a good look right where the NPs are holding a sign to.

No one wants to have a biopsy, if you can have an MRX. That => volumes of tests. = $$$$
As well as MRI same $$$$

The market, well, what is it ? Where buyer meets seller. Its what value is in the minds of its registry. If that registry is beaten, flogged, and demoralized, it probably couldnt tie its shoe lases to enter a running race. That registry needs to be reminded that behind those clouds of doom, and depression, there is a burning ball of light in the sky that can change the conga line of medical diagnostics, with $billions attached to it.

They need to get the market, a refreshed registry, into confidence of progression, and prize once more.
What about getting some strategic partner to put some coin in, like Siemens ? etc. ?